Navigation Links
Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Date:5/22/2008

Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "In addition, the excellent preclinical properties of RDEA427 and its long half-life in humans make it the perfect candidate to progress into clinical testing. Developing both RDEA806 and RDEA427 in tandem is consistent with our business strategy of keeping Ardea's pipeline full of novel compounds in areas that are underserved by current treatment options. We are on track to begin a Phase 1 trial with RDEA427 later this year, and expect to initiate a Phase 2b trial with RDEA806 in the third quarter of this year."

About RDEA806 and RDEA427

RDEA806 and RDEA427 are novel, structurally different NNRTIs for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 and RDEA427 may have important competitive advantages. These include: the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb); a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs. RDEA806 reproductive toxicity data indicates that future studies, including Ardea's planned Phase 2b trial, would likely include women of child-bearing age in anti-retroviral naive HIV-infected patients.

About Ardea Biosciences

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
2. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
3. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Calif., May 17, 2011 Codexis, Inc. (Nasdaq: ... investor conferences during June.   The company will ... Conference, to be held in New York, NY on June ... will appear on a panel titled "Renewable Biomaterials", scheduled for ...
... Colo., May 17, 2011 Medivance®, Inc. today announced ... Ernst & Young Entrepreneur Of The Year ® ... & Young LLP, the awards program recognizes entrepreneurs who ... innovation, financial performance and personal commitment to their businesses ...
Cached Medicine Technology:Codexis to Present at 3 Investor Conferences in June 2Medivance President and CEO Robert Kline Named Ernst & Young Entrepreneur Of The Year® 2011 Mountain Desert Region Award Finalist 2Medivance President and CEO Robert Kline Named Ernst & Young Entrepreneur Of The Year® 2011 Mountain Desert Region Award Finalist 3
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... When head lice hits a home or school, parents ... rid of it while keeping it from taking over the ... the solution right in their neighborhood: Lice Troopers . ... full spectrum head lice screening and treatment services to families ... Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , ...
(Date:12/25/2014)... is common during the holidays, but there are strategies that ... "Don,t arrive at a party hungry. It may seem logical ... a party, but deprivation leads to hunger, and hunger leads ... in Mount Kisco, N.Y., said in a hospital news release. ... even to have a snack before attending a party when ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... Gadolinium based contrast agents, frequently used during computed tomography (CT) ... associated with a very low rate of adverse effects, according ... of the American Journal of Roentgenology ( AJR ... Rochester, MN, included a total of 456,930 contrast doses administered. ...
... NASHVILLE, Tenn., Sept. 21 The bump on his ... out of surgical specialty training, craniofacial and maxillofacial surgeon Dr. Stephen ... hospital. Then came the biopsy results: the little nuisance was in ... After the first round of surgical procedures, Cantrell enrolled in a ...
... , Second Annual Event Promotes ... WASHINGTON, Sept. 20 Secretary of Veterans Affairs Eric K. Shinseki offered ... of the 2nd National Veterans Summer Sports Clinic in San Diego. ... Shinseki kicked-off the clinic by telling his personal story of dealing with ...
... let their legs move, bear weight without brain signals ... approach to treating spinal cord injuries allowed paralyzed rats ... report. , Spinal cord injuries result in paralysis when ... the brain are damaged or severed. Much of the ...
... NEW ORLEANS, Sept. 20 Jack Mackenroth, from the hit ... 20th annual NO/AIDS Walk and is bringing Living Positive By ... city. On Sunday, September 20th, Jack will participate in the Walk ... several other AIDS Service Organizations in Louisiana each year. The ...
... ... treatment program in the U.S., reNEW MAN (renewman.com) is promoting its national network of ... and older, the company helps connect professional men that exhibit signs of low testosterone ... safe-individualized treatments. , ...
Cached Medicine News:Health News:Surgeon Battling Own Cancer Developed New Treatment 2Health News:Surgeon Battling Own Cancer Developed New Treatment 3Health News:Secretary Shinseki Kicks-Off National Sports Clinic 2Health News:Paralyzed Rats Walk Again 2Health News:Paralyzed Rats Walk Again 3Health News:REPEAT: 'Project Runway' Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Design 2Health News:REPEAT: 'Project Runway' Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Design 3Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 2Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 3Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 4
... borescopes are rigid endoscopes for general applications and ... The diameters of borescopes, i.e. rigid endoscopes, range ... directions from 0 up to a 120 retrospection, ... and wide angle view. Endoscopes with working lengths ...
Patented* Design for Endoscopic Shunt Placement. Designed to pass through standard shunt ventricular catheters for optically guided placement....
... MVP Dura Substitute is the only dura ... requiring an immediate, watertight closure, and in ... desirable. Minimizing CSF leakage in cases requiring ... for techniques that require biological fixation and ...
... than a patch, Duragen is a ... mater. Duragen handles and conforms similar ... innovative collagen matrix for dural closure. ... of dural defects. Fully resorbed following ...
Medicine Products: